AUCATZYL (Obecabtagene autoleucel)

Aucatzyl is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Aucatzyl may cause cytokine release syndrome (CRS) and neurological toxicities. Aucatzyl should not be administered in patients with an active infection, or CNS disorders. Safety and effectiveness have not been established in pediatric patients (1).